Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, PO Box 22700, 1100 DE, Amsterdam, The Netherlands.
Public Health Department, College of Medicine, Private Bag 360, Blantyre, Malawi.
Malar J. 2017 Oct 18;16(1):419. doi: 10.1186/s12936-017-2066-7.
Prompt and effective malaria treatment are key in reducing transmission, disease severity and mortality. With the current scale-up of artemisinin-based combination therapy (ACT) coverage, there is need to focus on challenges affecting implementation of the intervention. Routine indicators focus on utilization and coverage, neglecting implementation quality. A health system in rural Malawi was assessed for uncomplicated malaria treatment implementation in children.
A cross-sectional health facility survey was conducted in six health centres around the Majete Wildlife Reserve in Chikwawa district using a health system effectiveness approach to assess uncomplicated malaria treatment implementation. Interviews with health facility personnel and exit interviews with guardians of 120 children under 5 years were conducted.
Health workers appropriately prescribed an ACT and did not prescribe an ACT to 73% (95% CI 63-84%) of malaria rapid diagnostic test (RDT) positive and 98% (95% CI 96-100%) RDT negative children, respectively. However, 24% (95% CI 13-37%) of children receiving artemisinin-lumefantrine had an inappropriate dose by weight. Health facility findings included inadequate number of personnel (average: 2.1 health workers per 10,000 population), anti-malarial drug stock-outs or not supplied, and inconsistent health information records. Guardians of 59% (95% CI 51-69%) of children presented within 24 h of onset of child's symptoms.
The survey presents an approach for assessing treatment effectiveness, highlighting bottlenecks which coverage indicators are incapable of detecting, and which may reduce quality and effectiveness of malaria treatment. Health service provider practices in prescribing and dosing anti-malarial drugs, due to drug stock-outs or high patient load, risk development of drug resistance, treatment failure and exposure to adverse effects.
及时有效的疟疾治疗是减少传播、疾病严重程度和死亡率的关键。随着青蒿素为基础的联合疗法(ACT)覆盖范围的扩大,需要关注影响干预措施实施的挑战。常规指标侧重于利用和覆盖范围,忽视了实施质量。本研究评估了马拉维农村地区卫生系统中儿童治疗无并发症疟疾的实施情况。
采用卫生系统有效性方法,在奇克瓦瓦区马杰特野生动物保护区周围的六个卫生中心进行了一项横断面卫生机构调查,以评估无并发症疟疾治疗的实施情况。对卫生机构人员进行了访谈,并对 120 名 5 岁以下儿童的监护人进行了出院访谈。
卫生工作者适当开具了 ACT,分别对 73%(95%CI 63-84%)的疟疾快速诊断检测(RDT)阳性和 98%(95%CI 96-100%)RDT 阴性儿童未开具 ACT。然而,24%(95%CI 13-37%)接受青蒿素-咯萘啶的儿童剂量按体重计算不合适。卫生机构发现包括人员数量不足(平均:每 10000 人有 2.1 名卫生工作者)、抗疟药物缺货或未供应、以及不一致的卫生信息记录。59%(95%CI 51-69%)的儿童在出现症状后 24 小时内就诊。
该调查提出了一种评估治疗效果的方法,突出了覆盖指标无法发现的瓶颈,这些瓶颈可能会降低疟疾治疗的质量和效果。由于药物缺货或高患者负荷,卫生服务提供者在开具和剂量抗疟药物方面的做法,存在耐药性发展、治疗失败和暴露于不良反应的风险。